The Biomedical Advanced Research and Development Authority (BARDA) has exercised the final $12 million option to produce the remaining $202 million smallpox vaccine order.
The order would be supplied by JYNNEOS, encompassing the Smallpox and Monkeypox vaccine. The option covers the supply of additional liquid-frozen JYNNEOS doses manufactured in the JYNNEOS fill and finish facility this year.
“Our contracts with BARDA have been foundational for the establishment of a sustainable manufacturing and supply of critical vaccines for protecting the United States of America,” Paul Chaplin, president and CEO of Bavarian Nordic, said. “This year, we are launching operations in our newly established fill and finish plant, which enables us to bring the final step of commercial manufacturing of JYNNEOS in-house as the first product on the line, marking a significant milestone in our long-standing partnership with the U.S. government.”
Authorities indicated the total $202 million procurement contract includes the manufacturing of bulk vaccine and revenue recognized in the years 2020-2022.
According to authorities, the project has been partially supported with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority.